MARKET

AXDX

AXDX

Accelerate Diagnostics Inc
NASDAQ
0.9900
-0.0200
-1.98%
After Hours: 1.020 +0.03 +3.03% 16:43 03/28 EDT
OPEN
1.000
PREV CLOSE
1.010
HIGH
1.050
LOW
0.9800
VOLUME
86.63K
TURNOVER
0
52 WEEK HIGH
11.90
52 WEEK LOW
0.8325
MARKET CAP
20.07M
P/E (TTM)
-0.1618
1D
5D
1M
3M
1Y
5Y
Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates
NASDAQ · 15h ago
Recap: Accelerate Diagnostics Q4 Earnings
Accelerate Diagnostics reported its Q4 earnings on March 28, 2024. The company missed estimates by -44.0% and missed on revenue by $55 thousand. Accelerate Diagnostic is expected to announce its earnings on April 28. Last quarter the company missed on EPS by $0.11.
Benzinga · 15h ago
Accelerate Diagnostics GAAP EPS of -$0.89 misses by $0.27, revenue of $3M misses by $0.45M
Earnings News Accelerate Diagnostics GAAP EPS of -$0.89 misses by $0.27, revenue of $3M misses by Q4 GAAP revenue of $3 million misses by  $0 45 million. Accelerate diagnostics, Inc. (AXDX) expected to report Q4 results on March 28, 2024.
Seeking Alpha · 16h ago
*Accelerate Diagnostics 4Q R&D Expenses $5.6M >AXDX
Dow Jones · 16h ago
*Accelerate Diagnostics 4Q Loss/Shr 89c >AXDX
Dow Jones · 16h ago
*Accelerate Diagnostics 4Q Sales $3M >AXDX
Dow Jones · 16h ago
Press Release: Accelerate Diagnostics Reports -2-
Three months ended December 31, 2015, the company reported a total of $1.2 billion in sales. The company's total sales for the quarter was $23.9 billion. In the first quarter of 2016, sales were $21.7 billion. Sales are expected to rise to $28.5 billion by the end of the year.
Dow Jones · 16h ago
BRIEF-Accelerate Diagnostics Q4 Sales USD 3 Million
Reuters · 16h ago
More
About AXDX
Accelerate Diagnostics, Inc. is an in-vitro diagnostics company. The Company is engaged in providing solutions that improve patient outcomes through the diagnosis of serious infections. Its in-vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit. The Accelerate PhenoTest BC Kit, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk.

Webull offers Accelerate Diagnostics Inc stock information, including NASDAQ: AXDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AXDX stock methods without spending real money on the virtual paper trading platform.